Abstract: A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, an aromatic group, polymer, a targeting group, or a detectable moiety; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.

Abstract: A method of treating PIK3CA helical domain mutant cancer in a subject in need thereof includes administering to the subject therapeutically effective amounts of (i) an inhibitor of nuclear translocation of p85? and/or an EZH inhibitor in combination with (ii) a PI3K inhibitor.

Abstract: Devices and methods for blocking signal transmission through neural tissue. One step of a method includes placing a therapy delivery device into electrical communication with the neural tissue. The therapy delivery device includes an electrode contact having a high charge capacity material. A multi-phase direct current (DC) can be applied to the neural tissue without damaging the neural tissue. The multi-phase DC includes a cathodic DC phase and anodic DC phase that collectively produce a neural block and reduce the charge delivered by the therapy delivery device. The DC delivery can be combined with high frequency alternating current (HFAC) block to produce a system that provides effective, safe, long term block without inducing an onset response.

Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.

Abstract: A melt processed viral nanoparticle construct for delivery of virus or virus-like particles to a site of interest includes a degradable polymer matrix and a plurality of virus or virus-like particles encapsulated within the degradable polymer matrix. The nanoparticle construct upon administration to the site of interest providing a sustained release of the virus or virus-like particles and/or nanoparticles upon degradation of the polymer matrix.

Abstract: A composition includes a hydrogel that includes a plurality biodegradable natural polymer macromers crosslinked with a first agent and optionally a plurality of cells dispersed in the crosslinked macromers, the microgels are capable of being crosslinked with a second agent that is different than the first crosslinking agent.

Abstract: A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer.

Abstract: PSMA targeted conjugate compounds, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

Abstract: One aspect of the present disclosure relates to a system that can modulate the intensity of a neural stimulation signal over time. A pulse generator can be configured to generate a stimulation signal for application to neural tissue of an individual and modulate a parameter related to intensity of a pattern of pulses of the stimulation signal over time. An electrode can be coupled to the pulse generator and configured to apply the stimulation signal to the neural tissue. A population of axons in the neural tissue can be recruited with each pulse of the stimulation signal.

Abstract: A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I).

Abstract: Compounds and pharmaceutical compositions thereof for inducing apoptosis in a cell expressing Bcl-2 and IP3R and their use in a method for treating neoplastic disorders in a subject.

Abstract: A method of promoting compensatory plasticity of spared neural cells after a neural injury includes contacting the spared neural cells with an effective amount of a therapeutic agent comprising a therapeutic peptide, wherein the therapeutic peptide comprises an amino acid sequence with at least 70% identity to SEQ ID NO:32.

Abstract: One aspect of the present disclosure relates to an isolated mutant human estrogen receptor alpha (hER?) that may be used in methods of drug discovery. The isolated mutant hER? can include a DNA-binding domain (DBD), a ligand-binding domain (LBD), and an interface between the DBD and the LBD, wherein at least one tryptophan residue is mutated to a phenylalanine residue.

Abstract: Systems, methods, and other embodiments associated with characterizing Radio Frequency Ablation (RFA) lesions using Optica Coherence Tomography (OCT) are described. One example method includes acquiring an OCT signal from a Region Of Interest (ROI) in an ablated material. The example method may also include determining whether a lesion was formed by the ablation by analyzing optical properties of the ROI as recorded in the OCT signal.

Abstract: Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.

Abstract: A method of treating a neurodegenerative disease in a subject includes administering to the subject a therapeutically effective amount of a TDP-43 mitochondrial localization inhibitor.

Abstract: A transformable wheel assembly includes a spoke frame and a central gear coupled to the spoke frame. A plurality of legs are pivotably coupled to the spoke frame. The plurality of legs include an arcuate outer surface and an arcuate distal interior edge. A plurality of leg teeth are formed on the arcuate distal interior edge. The leg teeth engage the central gear such that the central gear drives the plurality of legs between a closed position and an open position based on a direction of rotation of the central gear.

Abstract: A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of 8,9-unsaturated sterols in the OPCs, the agent comprising a compound having the formula (I): wherein variables Y1, R1 and R2 are as defined herein.

Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.